RALEIGH, N.C.--(BUSINESS WIRE)--BioDelivery Sciences International, Inc. (Nasdaq:BDSI)(http://www.biodeliverysciences.com) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing BDSI’s new drug application (NDA) for BEMA™ Fentanyl that was submitted on October 31, 2007, for the management of breakthrough cancer pain in opioid tolerant patients. The acceptance of the filing means the FDA has made an initial determination that the NDA is sufficiently complete to warrant a substantive review. A final decision by FDA is expected in August 2008.
